1. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience.
- Author
-
Babel N, Gabdrakhmanova L, Juergensen JS, Eibl N, Hoerstrup J, Hammer M, Rosenberger C, Hoeflich C, Frei U, Rohde F, Volk HD, and Reinke P
- Subjects
- Cytomegalovirus Infections epidemiology, Humans, Pilot Projects, Retrospective Studies, Valganciclovir, Antiviral Agents therapeutic use, Cytomegalovirus Infections drug therapy, Ganciclovir analogs & derivatives, Ganciclovir therapeutic use, Kidney Transplantation physiology, Postoperative Complications virology
- Abstract
Recent data suggest valganciclovir (VGC) to be as effective as ganciclovir for cytomegalovirus (CMV) prophylaxis. The objective of this study was to analyze the effect of oral valganciclovir in renal transplant patients with symptomatic CMV infection. Twenty-one patients with symptomatic CMV infection received VGC in doses adjusted to renal function until resolution of CMV antigenemia. The patients were followed for a mean of 5.5 months. During therapy, CMV antigenemia dropped in all patients from pretreatment positive levels of 5.2 +/- 3.7 to negative values of 0.25 +/- 0.2 positive cells/10,000 PBMC (P<0.001). After cessation of therapy, none of patients developed relapse of CMV antigenemia/symptoms within the follow-up. VGC therapy was well tolerated in all patients and no major adverse effects occurred. This pilot trial showed VGC to be safe and highly effective in antiviral therapy after renal transplantation. However, subsequent multicenter clinical trials for treatment of CMV disease are necessary.
- Published
- 2004
- Full Text
- View/download PDF